首页> 外文OA文献 >Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)

【2h】

Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)

机译：在当地先进的阶段IIIA-B NSCLC中具有标准同时化疗的无进展和整体存活的同时性化学疗法IIIA-B NSCLC：欧洲胸部肿瘤学平台尼古拉斯二期试验结果（欧洲胸脑肿瘤6-14）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Solange Peters; Enriqueta Felip; Urania Dafni; Amanda Tufman; Matthias Guckenberger; Ruth Álvarez; Ernest Nadal; Annemarie Becker; Hansjörg Vees; Miklos Pless; Alex Martinez-Marti; Maarten Lambrecht; Nicolaus Andratschke; Zoi Tsourti; Anne-Christine Piguet; Heidi Roschitzki-Voser; Adrian Gasca-Ruchti; Johan Vansteenkiste; Rolf A. Stahel; Dirk De Ruysscher;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14) [J] . Peters Solange, Felip Enriqueta, Dafni Urania, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2021,第2期

机译：在当地先进的阶段IIIA-B NSCLC中具有标准同时化疗的无进展和整体生存，并在局部高级阶段进行标准同时进行化学疗法：欧洲胸部肿瘤学平台尼古拉斯第二阶段试验（欧洲胸脑肿瘤平台6-14）
2. Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatin in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer: a Phase III Trial of the Japan Clinical Oncology Group (JCOG9812). [J] . Atagi S, Kawahara M, Tamura T, Japanese journal of clinical oncology. . 2005,第4期

机译：在局部晚期非小细胞肺癌老年患者中进行或不进行每日低剂量卡铂治疗的标准胸腔放疗：日本临床肿瘤学小组（JCOG9812）的III期试验。
3. Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP) [J] . Dziadziuszko Rafal, Smit Egbert F., Dafni Urania, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2019,第6期

机译：AFATINIB在NSCLC中具有HER2突变：欧洲胸脑肿瘤平台的前瞻性，开放标签II的结果（ETOP）
4. GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy [O] . Qing Zhou, Ming Chen, Gang Wu, 2020

机译：Gemstone-301：CS1001的III期临床试验作为局部晚期/不可切除（第III阶段）非小细胞肺癌（NSCLC）在先前同时/顺序化学疗法后没有疾病进展的患者的固结治疗
5. Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatin in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer: a Phase III Trial of the Japan Clinical Oncology Group (JCOG9812) [O] . Shinji Atagi, Masaaki Kawahara, Tomohide Tamura, 2004

机译：标准胸部放疗，有或没有同时每日低剂量卡铂，用于治疗局部晚期非小细胞肺癌的老年患者：日本临床肿瘤学组的一项III期试验（JCOG9812）

Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)

著录项

相似文献

相关主题

期刊订阅